ISO / IsoPlexis Corp - SEC-arkiveringer, Årsrapport, Fullmaktsdokument

ISO / IsoPlexis Corp / Northpond Ventures, LP - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* IsoPlexis Corporation (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 465005106 (CUSIP Number) Paul Hodgdon c/o Northpond Ventures, LLC 7500 Old Georgetown Road, Suite 800 Bethesda, MD 20814 240-800-1200 (Name, Ad

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-40894 IsoPlexis Corporation (Exact name of registrant as specified in its c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2023 IsoPlexis Corporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2023 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ISOPLEXIS CORPORATION

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ISOPLEXIS CORPORATION FIRST: The name of the corporation is IsoPlexis Corporation (the “Corporation”). SECOND: The address of the Corporation's registered office in the State of Delaware is 3500 South Dupont Highway, in the City of Dover, Delaware 19901, County of Kent. The name of the Corporation’s registered agent at such address i

AMENDED AND RESTATED ISOPLEXIS CORPORATION ARTICLE I

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ISOPLEXIS CORPORATION ARTICLE I OFFICES SECTION 1. REGISTERED OFFICE. The registered office shall be established and maintained at the office of Incorporating Services, Ltd., in the City of Dover, in the County of Kent, in the State of Delaware, and said corporation shall be the registered agent of this corporation in charge thereof. SECTION 2. OTHER OFFI

SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT dated as of March 21, 2023 PHENOMEX INC., as Borrower, ISOPLEXIS CORPORATION, as a Guarantor, EAST WEST BANK, as Bank TABLE OF CONTENTS

Exhibit 10.1 SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT dated as of March 21, 2023 among PHENOMEX INC., as Borrower, ISOPLEXIS CORPORATION, as a Guarantor, and EAST WEST BANK, as Bank TABLE OF CONTENTS 1. DEFINITIONS AND CONSTRUCTION. 1 1.1. Definitions. 1 1.2. Accounting Terms. 1 1.3. Other Definitional Terms; Rules of Interpretation. 2 1.4. Effectuation of Certain Transactions 3 1.5

As filed with the Securities and Exchange Commission on March 21, 2023

As filed with the Securities and Exchange Commission on March 21, 2023 Registration No.

As filed with the Securities and Exchange Commission on March 21, 2023

As filed with the Securities and Exchange Commission on March 21, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

425 1 brhc10049893425.htm 425 false0001615055NASDAQ00016150552023-03-162023-03-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2023 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2023 Berkeley Lights, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2023 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 9, 2023 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 9, 2023 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

DEFA14A 1 brhc10049510defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☑ Filed by a Party other than the Registrant  ☐ Check the appropriate

Filed by Berkeley Lights, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: IsoPlexis Corporation Commission File No.: 001-40894 Date: March 7, 202

Filed by Berkeley Lights, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: IsoPlexis Corporation Commission File No.: 001-40894 Date: March 7, 2023 On March 7, 2023, Broadridge Financial Solutions, Inc. mailed the below letter to certain stockholders of Berkeley Lights. March 7, 2023 Dear Fellow

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 Berkeley Lights, In

false000168965700016896572023-03-062023-03-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Description of Capital Stock

ISOPLEXIS CORPORATION DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description summarizes the material terms of the capital stock of IsoPlexis Corporation (the “Company,” “we,” or “us”) and provisions of our amended and restated certificate of incorporation and our amended and restated bylaws.

Fourth Amendment to Credit Agreement and Guaranty, dated as of December 28, 2022, bu and among IsoPlexis Corporation, Perceptive Credit Holdings III, L.P. as administrative agent, and the other parties thereto

isoplexis-4thamendmentfo EXECUTION VERSION 4886-8105-0172 7027014 FOURTH AMENDMENT TO CREDIT AGREEMENT AND GUARANTY This Fourth Amendment to Credit Agreement and Guaranty (herein, this “Agreement”) is entered into as of December 28, 2022 (the “Fourth Amendment Effective Date”), by and among IsoPlexis Corporation, a Delaware corporation (the “Borrower”), the Lenders party hereto (each a “Lender” and collectively, the “Lenders”) and Perceptive Credit Holdings III, LP, a Delaware limited partnership, as a lender and as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the “Administrative Agent”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40894 IsoPlexis Corporation (Exact name of Registrant as Specified in its Charter) Delaware 46-2179799 (State or Other Jurisdiction of Incorporation or Organization) (I.

Limited Waiver, dated February 13, 2023, by and among IsoPlexis Corporation, Perceptive Credit Holdings, L.P., as administrative agent, and the other parties thereto

limitedwaiverdatedfebrua 3/1/23, 8:10 PM SEC Filing | IsoPlexis https://investors.

Voting Agreement, dated as of December 21, 2022, among Berkeley Lights, Inc., Iceland Merger Sub Inc., IsoPlexis Corporation and the stockholders party thereto

isoplexispressrelease202 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2022 IsoPlexis Corporation (Exact name of Registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission File No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☑ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confi

Code of Business Conduct and Ethics

isoplexis-codeofbusiness [[5670504]] IsoPlexis Corporation Code of Business Conduct and Ethics Adopted by the Board of Directors August 16, 2021 Effective upon the effectiveness of the registration statement relating to IsoPlexis Corporation’s initial public offering IsoPlexis Corporation and its subsidiaries (the “Company”, “IsoPlexis”, “we” or “our”) require and expect the highest standards of professional and ethical conduct from our employees, officers and directors (“you”).

Limited Waiver, dated November 8, 2022, by and among IsoPlexis Corporation, Perceptive Credit Holdings, L.P., as administrative agent, and the other parties thereto

limitedwaiverdatednovemb

Amendment No. 1 to Patent Purchase Agreement, dated as of June 10, 2022, by and among QIAGEN Sciences, LLC, QIAGEN GmbH and IsoPlexis

iso-patentpurchaseagreem [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

Limited Waiver, dated March 1, 2023, by and among IsoPlexis Corporation, Perceptive Credit Holdings, L.P., as administrative agent, and the other parties thereto

iso-limitedwaiverforwork [[6024628]] LIMITED WAIVER This Limited Waiver, dated as of March 1, 2023 (this “Waiver”), is entered into by and among ISOPLEXIS CORPORATION, a Delaware corporation (the “Borrower”), the Lenders party hereto constituting Majority Lenders and Perceptive Credit Holdings III, LP, a Delaware limited partnership, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the “Administrative Agent”).

Subsidiaries of the Registrant

Exhibit 99.1 Isoplexis Corporation List of Subsidiaries of the Registrant IsoPlexis UK Limited (organized under the laws of the United Kingdom) IsoPlexis (Shanghai) Trading Co., Ltd. (organized under the laws of the People’s Republic of China)

Filed by Berkeley Lights, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: IsoPlexis Corporation Commission File No.: 001-40894 Date: February 28,

425 1 ny20007812x2425.htm FORM 425 Filed by Berkeley Lights, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: IsoPlexis Corporation Commission File No.: 001-40894 Date: February 28, 2023 On February 28, 2023, Broadridge Financial Solutions, Inc. mailed the below letter to certain stockholders of

Limited Waiver

Exhibit 10.1 EXECUTION VERSION Limited Waiver This Limited Waiver, dated as of February 13, 2023 (this “Waiver”), is entered into by and among IsoPlexis Corporation, a Delaware corporation (the “Borrower”), the Lenders party hereto constituting Majority Lenders and Perceptive Credit Holdings III, LP, a Delaware limited partnership, as administrative agent for the Lenders (in such capacity, togethe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2023 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Limited Waiver

Exhibit 10.1 EXECUTION VERSION Limited Waiver This Limited Waiver, dated as of February 13, 2023 (this “Waiver”), is entered into by and among IsoPlexis Corporation, a Delaware corporation (the “Borrower”), the Lenders party hereto constituting Majority Lenders and Perceptive Credit Holdings III, LP, a Delaware limited partnership, as administrative agent for the Lenders (in such capacity, togethe

Limited Waiver

Exhibit 10.1 EXECUTION VERSION Limited Waiver This Limited Waiver, dated as of February 13, 2023 (this “Waiver”), is entered into by and among IsoPlexis Corporation, a Delaware corporation (the “Borrower”), the Lenders party hereto constituting Majority Lenders and Perceptive Credit Holdings III, LP, a Delaware limited partnership, as administrative agent for the Lenders (in such capacity, togethe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2023 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☑ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Con

US4650051067 / IsoPlexis Corp / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* IsoPlexis Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 465005 106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

US4650051067 / IsoPlexis Corp / Spring Mountain Capital G.P., LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm236799d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IsoPlexis Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 465005106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Che

AGREEMENT

EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2023 PERCEPTIVE ADVISORS LLC

US4650051067 / IsoPlexis Corp / North Sound Trading, LP - AMENDMENT NO. 1 Passive Investment

SC 13G/A 1 eh23032991313ga1-iso.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IsoPlexis Corp. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 465005106 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the ap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☑ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Prox

Filed by Berkeley Lights, Inc.

Filed by Berkeley Lights, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: IsoPlexis Corporation Commission File No.: 001-40894 Date: February 7, 2023 The following presentation slides were presented by Sean Mackay, Chief Executive Officer of IsoPlexis Corporation (“IsoPlexis”), Siddhartha Kadia

Filed by IsoPlexis Corporation

Filed by IsoPlexis Corporation Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: IsoPlexis Corporation Commission File No.

US4650051067 / IsoPlexis Corp / CONNECTICUT INNOVATIONS INC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No.

US4650051067 / IsoPlexis Corp / DANAHER CORP /DE/ - SCHEDULE 13G - AMENDMENT 1 Passive Investment

SC 13G/A 1 sc13g-a1.htm SCHEDULE 13G - AMENDMENT 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IsoPlexis Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 465005106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Stat

Employee FAQ As of January 27, 2023

Filed by IsoPlexis Corporation Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: IsoPlexis Corporation Commission File No.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 12, 2023 IsoPlexis Corporation (Exact name of Registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission

IsoPlexis Reports Preliminary Full Year 2022 Revenue

Exhibit 99.1 IsoPlexis Reports Preliminary Full Year 2022 Revenue BRANFORD, Conn., Jan. 12, 2023, GlobeNewsWire - IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full year ended December 31, 2022. Total revenue for the full year ended December 31, 2022 is

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 12, 2023 IsoPlexis Corpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 12, 2023 IsoPlexis Corporation (Exact name of Registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission

Filed by Berkeley Lights, Inc.

Filed by Berkeley Lights, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: IsoPlexis Corporation Commission File No.: 001-40894 Date: January 4, 2023 The following is an email sent by the Siddartha Kadia, the Chief Executive Officer of Berkeley Lights, Inc. (?Berkeley Lights?), to the employees

The following email was sent by Siddhartha Kadia, the Chief Executive Officer of Berkeley Lights, Inc. (“Berkeley Lights”) to all employees of IsoPlexis Corporation (“IsoPlexis”) on January 4, 2023:

Filed by IsoPlexis Corporation Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: IsoPlexis Corporation Commission File No.

Filed by Berkeley Lights, Inc.

Filed by Berkeley Lights, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: IsoPlexis Corporation Commission File No.: 001-40894 Date: December 22, 2022 The following is a transcript of the joint conference call and webcast hosted by Berkeley Lights, Inc. (“Berkeley Lights”) and IsoPlexis Corpora

Berkeley Lights Town Hall Strictly Private & Confidential December 22, 2022 Forward-Looking Statements Certain statements in this communication regarding the proposed transaction between Berkeley Lights and IsoPlexis, the expected timetable for compl

Filed by Berkeley Lights, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: IsoPlexis Corporation Commission File No.: 001-40894 Date: December 22, 2022 The following is a presentation made to the employees of Berkeley Lights, Inc. (?Berkeley Lights?) by Berkeley Lights management on December 22,

Filed by Berkeley Lights, Inc.

Filed by Berkeley Lights, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: IsoPlexis Corporation Commission File No.: 001-40894 Date: December 23, 2022 The following communication was made available by Siddhartha Kadia, the Chief Executive Officer of Berkeley Lights, Inc. (?Berkeley Lights?), on

US4650051067 / IsoPlexis Corp / Northpond Ventures, LP - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* IsoPlexis Corporation (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 465005106 (CUSIP Number) Paul Hodgdon c/o Northpond Ventures, LLC 7500 Old Georgetown Road, Suite 850 Bethesda, MD 20814 240-800-1200

REFINITIV STREETEVENTS EDITED TRANSCRIPT BLI.OQ - Berkeley Lights Inc to Acquire IsoPlexis Corp M&A Call EVENT DATE/TIME: DECEMBER 21, 2022 / 10:00PM GMT REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us ©2022 Refinitiv. All rights reserved. Re

425 1 form425.htm 425 REFINITIV STREETEVENTS EDITED TRANSCRIPT BLI.OQ - Berkeley Lights Inc to Acquire IsoPlexis Corp M&A Call EVENT DATE/TIME: DECEMBER 21, 2022 / 10:00PM GMT REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us ©2022 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior writt

Joint Filing Agreement by and among the Reporting Persons.

Exhibit A Exhibit A Joint Filing Agreement In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D.

Filed by Berkeley Lights, Inc.

Filed by Berkeley Lights, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: IsoPlexis Corporation Commission File No.: 001-40894 Date: December 21, 2022 The following communication was made available by Berkeley Lights, Inc. (“Berkeley Lights”) on Twitter on December 21, 2022 The following commun

EMPLOYEE FAQ

Exhibit 99.4 EMPLOYEE FAQ About The Acquisition 1. Why is Berkeley Lights acquiring IsoPlexis? ? Berkeley Lights and IsoPlexis are leaders in the functional assessment of live cells and are united in our dedication to changing the course of human health and enabling scientific breakthroughs. Between the two companies we have both cutting edge and highly complementary platforms and technology portf

Agreement and Plan of Merger, dated as of December 21, 2022, among IsoPlexis Corporation, Berkeley Lights, Inc. and Iceland Merger Sub Inc.*

Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER Dated as of December 21, 2022 Among ISOPLEXIS CORPORATION, BERKELEY LIGHTS, INC. and ICELAND MERGER SUB INC. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS; INTERPRETATION SECTION 1.01. Definitions 6 SECTION 1.02. Other Defined Terms 13 SECTION 1.03. Interpretation 16 ARTICLE II THE MERGER SECTION 2.01. The Merger 17 SECTION 2.02. Closing 17

Agreement and Plan of Merger, dated as of December 21, 2022, among IsoPlexis Corporation, Berkeley Lights, Inc. and Iceland Merger Sub Inc.

Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER Dated as of December 21, 2022 Among ISOPLEXIS CORPORATION, BERKELEY LIGHTS, INC. and ICELAND MERGER SUB INC. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS; INTERPRETATION SECTION 1.01. Definitions 6 SECTION 1.02. Other Defined Terms 13 SECTION 1.03. Interpretation 16 ARTICLE II THE MERGER SECTION 2.01. The Merger 17 SECTION 2.02. Closing 17

AGREEMENT AND PLAN OF MERGER Dated as of December 21, 2022 ISOPLEXIS CORPORATION, BERKELEY LIGHTS, INC. ICELAND MERGER SUB INC. TABLE OF CONTENTS

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER Dated as of December 21, 2022 Among ISOPLEXIS CORPORATION, BERKELEY LIGHTS, INC. and ICELAND MERGER SUB INC. TABLE OF CONTENTS Page Article I Definitions; Interpretation Section 1.01. Definitions 6 Section 1.02. Other Defined Terms 14 Section 1.03. Interpretation 16 Article II The Merger Section 2.01. The Merger 17 Section 2.02. Closing 17 Section 2.03. Eff

VOTING AGREEMENT

EX-10.1 3 ny20006362x2ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of December 21, 2022, is by and among Berkeley Lights, Inc., a Delaware corporation (“Parent”), Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), IsoPlexis Corporation, a Delaware corporation (the “Company”), and Igor Y

: Siddhartha Kadia

Exhibit 99.3 From: Siddhartha Kadia To: All Employees Date: Wednesday, December 21, 2022 Subject: Berkeley Lights to Acquire IsoPlexis Dear Berkeley Lights team, Today we are taking a pivotal step toward building a growing, profitable, and sustainable life sciences company by acquiring IsoPlexis. This will bring together two industry pioneers with talented teams and proven capabilities, united in

Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to In

EX-99.1 5 exhibit991-form8xk.htm EX-99.1 Exhibit 99.1 Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expe

Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to In

Exhibit 99.1 Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to

Voting Agreement, dated as of December 21, 2022, among IsoPlexis Corporation, Berkeley Lights, Inc., Iceland Merger Sub Inc. and the stockholders party thereto

Exhibit 10.2 EXECUTION VERSION VOTING AGREEMENT This Voting Agreement (this ?Agreement?), dated as of December 21, 2022, is by and among Berkeley Lights, Inc., a Delaware corporation (?Parent?), Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent (?Merger Sub?), IsoPlexis Corporation, a Delaware corporation (the ?Company?), and Igor Y. Khandros and Susan Bloch (

Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to In

Exhibit 99.1 Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to

Form 8-K

Exhibit 10.1 EXECUTION VERSION VOTING AGREEMENT This Voting Agreement (this ?Agreement?), dated as of December 21, 2022, is by and among Berkeley Lights, Inc., a Delaware corporation (?Parent?), Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent (?Merger Sub?), IsoPlexis Corporation, a Delaware corporation (the ?Company?), and the Persons listed on the attached

Voting Agreement, dated as of December 21, 2022, among Berkeley Lights, Inc., Iceland Merger Sub Inc., IsoPlexis Corporation and the stockholders party thereto

Exhibit 10.1 EXECUTION VERSION VOTING AGREEMENT This Voting Agreement (this ?Agreement?), dated as of December 21, 2022, is by and among Berkeley Lights, Inc., a Delaware corporation (?Parent?), Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent (?Merger Sub?), IsoPlexis Corporation, a Delaware corporation (the ?Company?), and the Persons listed on the attached

Berkeley Lights to Acquire IsoPlexis Investor Presentation December 21, 2022 Forward-Looking Statements Certain statements in this communication regarding the proposed transaction between Berkeley Lights and IsoPlexis, the expected timetable for comp

Berkeley Lights to Acquire IsoPlexis Investor Presentation December 21, 2022 Forward-Looking Statements Certain statements in this communication regarding the proposed transaction between Berkeley Lights and IsoPlexis, the expected timetable for completing the transaction, benefits and synergies of the transaction, future opportunities for the combined company and products and any other statements regarding Berkeley Lights' and IsoPlexis? future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are ?forward-looking? statements made within the meaning of the Private Securities Litigation Reform Act of 1995.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2022 Berkeley Lights

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2022 Berkeley Lights, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39388 35-2415390 (State or other jurisdiction (Commission (IRS Employer of

: Sean Mackay

Exhibit 99.3 From: Sean Mackay To: All Employees Subject: IsoPlexis & Berkeley Lights Merger: PhenomeX Hi everyone, It has been quite a year, and you?ve all worked very hard to help live the values & mission at IsoPlexis. Today, we are taking a pivotal step on our path toward building a growing, sustainable life sciences company by announcing our merger with Berkeley Lights (see our press release

Berkeley Lights to Acquire IsoPlexis Investor Presentation December 21, 2022 Forward-Looking Statements Certain statements in this communication regarding the proposed transaction between Berkeley Lights and IsoPlexis, the expected timetable for comp

Berkeley Lights to Acquire IsoPlexis Investor Presentation December 21, 2022 Forward-Looking Statements Certain statements in this communication regarding the proposed transaction between Berkeley Lights and IsoPlexis, the expected timetable for completing the transaction, benefits and synergies of the transaction, future opportunities for the combined company and products and any other statements regarding Berkeley Lights' and IsoPlexis? future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are ?forward-looking? statements made within the meaning of the Private Securities Litigation Reform Act of 1995.

Berkeley Lights to Acquire IsoPlexis Investor Presentation December 21, 2022 Forward-Looking Statements Certain statements in this communication regarding the proposed transaction between Berkeley Lights and IsoPlexis, the expected timetable for comp

EX-99.2 6 ny20006362x2ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Berkeley Lights to Acquire IsoPlexis Investor Presentation December 21, 2022 Forward-Looking Statements Certain statements in this communication regarding the proposed transaction between Berkeley Lights and IsoPlexis, the expected timetable for completing the transaction, benefits and synergies of the transaction, future opportunities for

Voting Agreement, dated as of December 21, 2022, among IsoPlexis Corporation, Berkeley Lights, Inc., Iceland Merger Sub Inc. and the stockholders party thereto

Exhibit 10.2 EXECUTION VERSION VOTING AGREEMENT This Voting Agreement (this ?Agreement?), dated as of December 21, 2022, is by and among Berkeley Lights, Inc., a Delaware corporation (?Parent?), Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent (?Merger Sub?), IsoPlexis Corporation, a Delaware corporation (the ?Company?), and Igor Y. Khandros and Susan Bloch (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2022 IsoPlexis Corpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2022 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction (Commission (IRS Employer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2022 IsoPlexis Corpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2022 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction (Commission (IRS Employer of

: Sean Mackay

EX-99.3 7 exhibit993-form8xk.htm EX-99.3 Exhibit 99.3 From: Sean Mackay To: All Employees Subject: IsoPlexis & Berkeley Lights Merger: PhenomeX Hi everyone, It has been quite a year, and you’ve all worked very hard to help live the values & mission at IsoPlexis. Today, we are taking a pivotal step on our path toward building a growing, sustainable life sciences company by announcing our merger wit

VOTING AGREEMENT

Exhibit 10.2 VOTING AGREEMENT This Voting Agreement (this ?Agreement?), dated as of December 21, 2022, is by and among Berkeley Lights, Inc., a Delaware corporation (?Parent?), Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent (?Merger Sub?), IsoPlexis Corporation, a Delaware corporation (the ?Company?), and the Persons listed on the attached Schedule A who ar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40894 IsoPlexis Corporation (Exact name of Registrant as Specified in its Charter) Delaware 46-2179799 (State or Other Jurisdiction of Incorporation or Organization) (I.

IsoPlexis Reports Third Quarter 2022 Financial Results

Exhibit 99.1 IsoPlexis Reports Third Quarter 2022 Financial Results BRANFORD, CONN., November 10, 2022 ? IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended September 30, 2022. Recent Highlights ?Revenue of $4.5 million for the third quarter 2022, representing a

Limited Waiver between Perceptive Credit Holdings III, LP and IsoPlexis Corporation, dated November 8, 2022

EXECUTION VERSION 4879-6997-9708 7027014 LIMITED WAIVER This Limited Waiver, dated as of November 8, 2022 (this ?Waiver?), is entered into by and among ISOPLEXIS CORPORATION, a Delaware corporation (the ?Borrower?), the Lenders party hereto constituting Majority Lenders and PERCEPTIVE CREDIT HOLDINGS III, LP, a Delaware limited partnership, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the ?Administrative Agent?).

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2022 IsoPlexis Corporation (Exact name of Registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission File No.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2022 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commissio

September 2022 EMPOWERING LABS, CHANGING HUMAN HEALTH Disclaimer and Forward-Looking Statements Forward-looking statements and other information This presentation contains “forward-looking statements.” These statements are made pursuant to the safe h

September 2022 EMPOWERING LABS, CHANGING HUMAN HEALTH Disclaimer and Forward-Looking Statements Forward-looking statements and other information This presentation contains ?forward-looking statements.

IsoPlexis Announces the Appointment of former Luminex Corporation Chairman and CEO, Nachum “Homi” Shamir to its Board of Directors

Exhibit 99.1 IsoPlexis Announces the Appointment of former Luminex Corporation Chairman and CEO, Nachum ?Homi? Shamir to its Board of Directors BRANFORD, Conn., August 23, 2022 ? IsoPlexis Corporation (Nasdaq: ISO) (?IsoPlexis?), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced the appointment of Nachum ?Homi? Shamir to its Board of

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 22, 2022 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40894 IsoPlexis Corporation (Exact name of Registrant as Specified in its Charter) Delaware 46-2179799 (State or Other Jurisdiction of Incorporation or Organization) (I.

IsoPlexis Reports Second Quarter 2022 Financial Results

Exhibit 99.1 IsoPlexis Reports Second Quarter 2022 Financial Results BRANFORD, CONN., August 10, 2022 ? IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended June 30, 2022. Recent Highlights ?Drove operational efficiencies and headcount reductions through our Redu

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2022 IsoPlexis Corporation (Exact name of Registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission File No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2022 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT IsoPlexis Corporation (Exact name of Registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT IsoPlexis Corporation (Exact name of Registrant as specified in its charter) Delaware 001-40894 (State or other jurisdiction of incorporation) (Commission File No.) 35 NE Industrial Road, Branford, CT 06405 (Address of principal executive offices and zip code) Richard Rew Senior Vice Presi

IsoPlexis Reports First Quarter 2022 Financial Results First quarter 2022 revenue increased 52% over prior year period

Exhibit 99.1 IsoPlexis Reports First Quarter 2022 Financial Results First quarter 2022 revenue increased 52% over prior year period BRANFORD, CONN., May 11, 2022 ? IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter ended March 31, 2022. Recent Highlights ?Revenue of $4.9 million for the first quarter 2022, representing a 52% increase

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2022 IsoPlexis Corporation (Exact name of Registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission File No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40894 IsoPlexis Corporation (Exact name of Registrant as Specified in its Charter) Delaware 46-2179799 (State or Other Jurisdiction of Incorporation or Organization) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON DC 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON DC 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON DC 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON DC 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

IsoPlexis Reports Preliminary First Quarter 2022 Revenue, Streamlines Operating Structure to Support Sustainable Growth Reiterates full year guidance and extends cash runway to H2 2024

Exhibit 99.1 IsoPlexis Reports Preliminary First Quarter 2022 Revenue, Streamlines Operating Structure to Support Sustainable Growth Reiterates full year guidance and extends cash runway to H2 2024 BRANFORD, Conn., April 11, 2022 (GLOBE NEWSWIRE) - IsoPlexis Corporation (Nasdaq: ISO) (?IsoPlexis?), the Superhuman Cell Company, today announced its preliminary unaudited revenue for the first quarter

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 6, 2022 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission Fil

under the 2021 Omnibus Incentive Compensation Plan (filed herewith)

Final V. 1.0 March 2022 [[5762903]] NOTICE OF RESTRICTED STOCK UNIT AWARD ISOPLEXIS CORPORATION 2021 OMNIBUS INCENTIVE COMPENSATION PLAN Unless otherwise defined herein or in the RSU Award Agreement (as defined below), capitalized terms used in this Notice of Restricted Stock Unit Award (this ?Notice of Grant?) shall have the same meanings ascribed to them in the Isoplexis Corporation 2021 Omnibus

As filed with the Securities and Exchange Commission on April 7, 2022

As filed with the Securities and Exchange Commission on April 7, 2022 Registration No.

Filing Fee Table (filed herewith)

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) IsoPlexis Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

Subsidiaries of the Registrant

Exhibit 99.1 Isoplexis Corporation List of Subsidiaries of the Registrant IsoPlexis UK Limited (organized under the laws of the United Kingdom) IsoPlexis (Shanghai) Trading Co., Ltd. (organized under the laws of the People?s Republic of China)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40894 IsoPlexis Corporation (Exact name of Registrant as Specified in its Charter) Delaware 46-2179799 (State or Other Jurisdiction of Incorporation or Organization) (I.

Description of Capital Stock

ISOPLEXIS CORPORATION DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description summarizes the material terms of the capital stock of IsoPlexis Corporation (the ?Company,? ?we,? or ?us?) and provisions of our amended and restated certificate of incorporation and our amended and restated bylaws.

Amended Warrant Certificate by and between IsoPlexis Corporation and Perceptive Credit Holdings III, LP dated March 30, 2022

Execution Version 1 4814-9458-5556 7027014 WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES IS EFFECTIVE UNDER THE SECURITIES ACT AND IS QUALIFIED UNDER APPLICABLE STATE AND FOREIGN LAW OR (II) THE TRANSACTION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS UNDER THE SECURITIES ACT AND THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN LAW.

Third Amendment to Credit Agreement and Guaranty, dated as of March 30, 2022, by and among IsoPlexis Corporation, Perceptive Credit Holdings III, L.P. as administrative agent, and the other parties thereto

EXECUTION VERSION 4886-8962-4086 7027014 THIRD AMENDMENT TO CREDIT AGREEMENT AND GUARANTY This Third Amendment to Credit Agreement and Guaranty (herein, this ?Agreement?) is entered into as of March 30, 2022 (the ?Third Amendment Effective Date?), by and among IsoPlexis Corporation, a Delaware corporation (the ?Borrower?), the Lenders party hereto (each a ?Lender? and collectively, the ?Lenders?) and Perceptive Credit Holdings III, LP, a Delaware limited partnership, as a lender and as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the ?Administrative Agent?).

IsoPlexis Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Revenue Outlook for 2022 2021 revenue increased 66% over prior year period

EX-99.1 2 exhibit991earningsrelease-.htm EX-99.1 Exhibit 99.1 IsoPlexis Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Revenue Outlook for 2022 2021 revenue increased 66% over prior year period BRANFORD, CONN., March 2, 2022 – IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter and year ended December 31, 2021

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2022 IsoPlexis Corporation (Exact name of Registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission File No.

AGREEMENT

EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them.

US4650051067 / IsoPlexis Corp / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* IsoPlexis Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 465005 106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th

US4650051067 / IsoPlexis Corp / BlackRock Inc. Passive Investment

us4650051067020422.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) IsoPlexis Corp - (Name of Issuer) Common Stock - (Title of Class of Securities) 465005106 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 28, 2022 IsoPlexis Corporation (Exact name of Registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the common stock of IsoPlexis Corporation is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange A

US4650051067 / IsoPlexis Corp / DANAHER CORP /DE/ - SC 13G Passive Investment

SC 13G 1 sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* IsoPlexis Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 465005106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriat

US4650051067 / IsoPlexis Corp / CONNECTICUT INNOVATIONS INC - SCHEDULE 13G Passive Investment

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? SCHEDULE 13G ? (Amendment No.

JOINT FILING AGREEMENT

EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of the Issuer and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.

US4650051067 / IsoPlexis Corp / Spring Mountain Capital G.P., LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IsoPlexis Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 465005106 (CUSIP Number) October 7, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2022 IsoPlexis Corporation (Exact name of Registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission

IsoPlexis Reports Preliminary Full Year 2021 Revenue, Releases Industry-First Superhuman Cell Library Superhero cells are key to the efficacy, potency, and durability of therapies across the human health spectrum

EX-99.1 2 exhibit9912021preliminaryr.htm EX-99.1 Exhibit 99.1 IsoPlexis Reports Preliminary Full Year 2021 Revenue, Releases Industry-First Superhuman Cell Library Superhero cells are key to the efficacy, potency, and durability of therapies across the human health spectrum BRANFORD, Conn., Jan. 9, 2022, (GLOBE NEWSWIRE) - IsoPlexis (NASDAQ: ISO), the Superhuman Cell Company, today announced its p

January 2021 Disclaimer and Forward-Looking Statements IsoPlexis Corporation (“IsoPlexis,” “we,” “us,” or the “Company”) has filed a prospectus on Form S-1 (File No. 333-258046) with the SEC for the offering to which this presentation relates. The re

January 2021 Disclaimer and Forward-Looking Statements IsoPlexis Corporation (?IsoPlexis,? ?we,? ?us,? or the ?Company?) has filed a prospectus on Form S-1 (File No.

Joint Filing Agreement, dated December 23, 2021, among North Sound Trading LP, North Sound Management, Inc., and Brian Miller (previously filed).

EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn

ISO / IsoPlexis Corp / North Sound Trading, LP - SCHEDULE 13G Passive Investment

SC 13G 1 eh21021217113g-iso.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IsoPlexis Corp. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 465005106 (CUSIP Number) December 17, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriat

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 10, 2021 IsoPlexis Corporation (Exact name of Registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission

greement under the 2021 Omnibus Incentive Compensation Plan (incorporated herein by reference to Exhibit 1

NOTICE OF RESTRICTED STOCK AWARD ISOPLEXIS CORPORATION 2021 OMNIBUS INCENTIVE COMPENSATION PLAN Unless otherwise defined herein or in the Restricted Stock Award Agreement (as defined below), capitalized terms used in this Notice of Restricted Stock Award (this ?Notice of Grant?) shall have the same meanings ascribed to them in the Isoplexis Corporation 2021 Omnibus Incentive Compensation Plan, as amended from time to time (the ?Plan?).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40894 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 46-2179799 (State or other jurisdiction of incorporation or organization) (I.

Notice of Stock Option Award Agreement under the 2021 Omnibus Incentive Compensation Plan

NOTICE OF STOCK OPTION AWARD ISOPLEXIS CORPORATION 2021 OMNIBUS INCENTIVE COMPENSATION PLAN Unless otherwise defined herein or in the Stock Option Agreement (as defined below), capitalized terms used in this Notice of Option Award (this ?Notice of Grant?) shall have the same meanings ascribed to them in the Isoplexis Corporation 2021 Omnibus Incentive Compensation Plan, as amended from time to time (the ?Plan?).

IsoPlexis Reports Third Quarter 2021 Financial Results Year-to-date 2021 revenue increased 68% over prior year period

Exhibit 99.1 IsoPlexis Reports Third Quarter 2021 Financial Results Year-to-date 2021 revenue increased 68% over prior year period BRANFORD, CONN., November 10, 2021 ? IsoPlexis Corporation (Nasdaq: ISO), the leader in functional single-cell proteomics, today reported financial results for the quarter ended September 30, 2021. Recent Highlights ?Revenue of $4.2 million for the third quarter of 202

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2021 IsoPlexis Corporation (Exact name of Registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission File No.

Second Amendment to Credit Agreement and Guaranty, dated October 29, 2021, by and among IsoPlexis Corporation, the Lenders party thereto and Perceptive Credit Holdings III, LP, as a lender and administrative agent

EX-10.1 2 ex10-1.htm SECOND AMENDMENT TO CREDIT AGREEMENT AND GUARANTY Exhibit 10.1 Execution Version Second Amendment to Credit Agreement and Guaranty This Second Amendment to Credit Agreement and Guaranty (herein, this “Agreement”) is entered into as of October 29, 2021 (the “Second Amendment Effective Date”), by and among IsoPlexis Corporation, a Delaware corporation (the “Borrower”), the Lende

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

8-K 1 form8-k.htm CURRENT REPORT false000161505500016150552021-10-292021-10-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2021 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 0

Joint Filing Agreement by and among the Reporting Persons.

IsoPlexis Corporation SC 13D Exhibit A Joint Filing Agreement In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D.

AGREEMENT

EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them.

ISO / IsoPlexis Corp / Northpond Ventures, LP - ACQUISITION OF BENEFICIAL OWNERSHIP Activist Investment

SC 13D 1 iso-sc13d101221.htm ACQUISITION OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* IsoPlexis Corporation (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 465005106 (CUSIP Number) Paul Hodgdon c/o Northpond Ventures, LLC 7500 Old Geor

ISO / IsoPlexis Corp / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IsoPlexis Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 465005 106 (CUSIP Number) October 12, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru

Amended and Restated By-laws of IsoPlexis Corporation.

EX-3.2 4 exhibit32-8xk.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ISOPLEXIS CORPORATION A Delaware corporation (Adopted as of October 12, 2021) IsoPlexis Corporation (the “Corporation”), pursuant to the provisions of Section 109 of the General Corporation Law of the State of Delaware (the “DGCL”), hereby adopts these Amended and Restated By-laws (these “By-laws”), which restate, amend

Underwriting Agreement, dated October 7, 2021, by and among IsoPlexis Corporation and Morgan Stanley & Co. LLC, Cowen and Company, LLC, Evercore Group, L.L.C. and SVB Leerink LLC, as representatives of the several underwriters specified therein.

Exhibit 1.1 Execution Version 8,333,000 Shares ISOPLEXIS CORPORATION COMMON STOCK, PAR VALUE $0.001 UNDERWRITING AGREEMENT October 7, 2021 October 7, 2021 Morgan Stanley & Co. LLC Cowen and Company, LLC Evercore Group, L.L.C. SVB Leerink LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Cowen and Company, LLC 599 Lexington Avenue, 27th Floor New York, New York 10022 c/o E

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 7, 2021 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware 001-40894 46-2179799 (State or other jurisdiction of incorporation) (Commission F

Offer Letter, dated September 27, 2021, by and between IsoPlexis Corporation and Richard W. Rew II.

EX-10.1 5 exhibit101-8xk.htm EX-10.1 Exhibit 10.1 September 27, 2021 Richard Rew Dear Richard, I am very pleased to provide you with a summary of the terms and conditions of your anticipated employment by IsoPlexis Corporation (the “Company”). The following sets forth the proposed terms and conditions of your offer of employment. This offer expires on September 30, 2021. We hope that you choose to

Eighth Amended and Restated Certificate of Incorporation of IsoPlexis Corporation.

EX-3.1 3 exhibit31-8xk.htm EX-3.1 Exhibit 3.1 Execution Version EIGHTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ISOPLEXIS CORPORATION * * * * * ISOPLEXIS CORPORATION, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: FIRST: The Corporation was incorporated by the filing of its original Certificate of Incorp

IsoPlexis Announces Closing of Public Offering

EX-99.1 6 exhibit991-8xk.htm EX-99.1 Exhibit 99.1 IsoPlexis Announces Closing of Public Offering BRANFORD, Conn., October 12, 2021 – IsoPlexis Corporation (“IsoPlexis”), a leader in functional single-cell proteomics, today announced the closing of its initial public offering of 8,333,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds from the offering, be

8,333,000 Shares COMMON STOCK

Filed Pursuant to Rule 424(b)(4) Registration No.: 333-258046 PROSPECTUS 8,333,000 Shares COMMON STOCK This is an initial public offering of shares of the common stock of IsoPlexis Corporation. We are offering 8,333,000 shares to be sold in this offering. Prior to this offering, there has been no public market for our common stock. The initial public offering price per share is $15.00. Our common

Employee Stock Purchase Plan (filed herewith)

EX-99.3 5 exhibit993-sx8.htm EX-99.3 Exhibit 99.3 ISOPLEXIS CORPORATION 2021 EMPLOYEE STOCK PURCHASE PLAN Approved by the Board of Directors on August 16, 2021 Approved by Stockholders on September 27, 2021 Effective on October 7, 2021 1.Purpose. The Plan consists of two components: a component that is intended to qualify as an “employee stock purchase plan” under Section 423 of the Code (the “423

IsoPlexis Corporation 2021 Omnibus Incentive Compensation Plan (filed herewith)

Exhibit 99.2 ISOPLEXIS CORPORATION 2021 OMNIBUS INCENTIVE COMPENSATION PLAN SECTION 1. Purpose. The purpose of this 2021 Omnibus Incentive Compensation Plan (the ?Plan?) is to enable the Company (as defined below) to grant equity compensation awards and other types of incentive compensation. The Plan is intended to replace the Prior Plan (as defined below), which shall be automatically terminated

As filed with the Securities and Exchange Commission on October 8, 2021.

As filed with the Securities and Exchange Commission on October 8, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IsoPlexis Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 46-2179799 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S.

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 IsoPlexis Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2179799 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 35 NE Industrial Rd

ISOPLEXIS CORPORATION 35 NE Industrial Rd Branford, CT 06405

ISOPLEXIS CORPORATION 35 NE Industrial Rd Branford, CT 06405 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Jane Park Ms. Christine Westbrook IsoPlexis Corporation Registration Statement on Form S-1 File No. 333-258046 October 5, 2021 Dear Mmes. Park and Westbrook: Pursuant to Rule 4

[signature page follows]

CORRESP 1 filename1.htm October 5, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeanne Bennett Kevin Vaughn Jane Park Christine Westbrook Re: IsoPlexis Corporation Registration Statement on Form S-1 (File No. 333-258046) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933,

Consent of Richard W. Rew II

Exhibit 99.1 CONSENT OF OFFICER NOMINEE In connection with the filing by IsoPlexis Corporation of the Registration Statement on Form S-1, as amended (the ?Registration Statement?), with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to the Securities Act, to being named as IsoPlexis Corporation?s Senior Vice Pr

As filed with the Securities and Exchange Commission on October 1, 2021.

As filed with the Securities and Exchange Commission on October 1, 2021. Registration No. 333-258046 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organiza

Form of Indemnification Agreement

EX-10.19 3 exhibit1019-sx1a2.htm EX-10.19 Exhibit 10.19 FORM OF INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [●], 2021, between IsoPlexis Corporation, a Delaware corporation (the “Company”), and [●] (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other

Form of Lock-up Agreement (incorporated by reference to Exhibit A to Exhibit 1.1 to the Issuer’s Registration Statement on Form S-1 (SEC File No. 333-258046), filed with the SEC on October 1, 2021).

Exhibit 1.1 [●] Shares ISOPLEXIS CORPORATION COMMON STOCK, PAR VALUE $0.001 UNDERWRITING AGREEMENT [●], 2021 [●], 2021 Morgan Stanley & Co. LLC Cowen and Company, LLC Evercore Group, L.L.C. SVB Leerink LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Cowen and Company, LLC 599 Lexington Avenue, 27th Floor New York, New York 10022 c/o Evercore Group, L.L.C. 55 East 52nd S

As filed with the Securities and Exchange Commission on September 23, 2021.

As filed with the Securities and Exchange Commission on September 23, 2021. Registration No. 333-258046 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organ

Amended and Restated Bylaws of IsoPlexis Corporation

EX-3.2 3 exhibit32-sx1a1.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ISOPLEXIS CORPORATION A Delaware corporation (Adopted as of , 2021) IsoPlexis Corporation (the “Corporation”), pursuant to the provisions of Section 109 of the General Corporation Law of the State of Delaware (the “DGCL”), hereby adopts these Amended and Restated By-laws (these “By-laws”), which restate, amend and supe

IsoPlexis Corporation Non-Employee Director Compensation Program*

Exhibit 10.18 IsoPlexis Corporation NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Effective upon the closing of the Company’s initial public offering The purpose of this Non-Employee Director Compensation Program (the “Program”) of IsoPlexis Corporation, a Delaware corporation (the “Company”), is to promote the interests of the Company’s stockholders by providing a total compensation package that att

Amended and Restated Certificate of Incorporation of IsoPlexis Corporation

Exhibit 3.1 EIGHTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ISOPLEXIS CORPORATION * * * * * ISOPLEXIS CORPORATION, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: FIRST: The Corporation was incorporated by the filing of its original Certificate of Incorporation with the Delaware Secretary of State on Marc

IsoPlexis Corporation Registration Statement on Form S-1 Filed July 20, 2021 File No. 333-258046

August 20, 2021 IsoPlexis Corporation Registration Statement on Form S-1 Filed July 20, 2021 File No.

Letter Agreement, dated April 12, 2021, by and between IsoPlexis Corporation and Siddhartha Kadia

Exhibit 10.11 IsoPlexis Corporation 35 NE Industrial Road Branford, Connecticut 06405 April 21, 2021 Siddhartha Kadia Re: Director Arrangement Dear Siddhartha: I am pleased to confirm our agreement regarding your service to IsoPlexis Corporation, a Delaware corporation, (the “Company”) as a director. We are very pleased to have you on board. This letter sets forth the agreement between you and the

IsoPlexis Corporation 2021 Employee Stock Purchase Plan

EX-10.17 13 exhibit1017-sx1a1.htm EX-10.17 Exhibit 10.17 ISOPLEXIS CORPORATION 2021 EMPLOYEE STOCK PURCHASE PLAN Approved by the Board of Directors on August 16, 2021 Approved by Stockholders on [●] Effective on [●] 1.Purpose. The Plan consists of two components: a component that is intended to qualify as an “employee stock purchase plan” under Section 423 of the Code (the “423 Component”) and a c

Form of Common Stock Certificate of IsoPlexis Corporation

Exhibit 4.1 THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER?AGENT AND?REGISTRAR, FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF IsoPlexis Corporation (hereinafter called the ?Company?), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate properly endor

Amended and Restated Investors’ Rights Agreement, dated as of December 30, 2020, by and among IsoPlexis Corporation and the other parties thereto

Exhibit 4.2 Execution Copy [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type that the registrant customarily and actually treats as private and confidential. SIXTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS SIXTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreem

IsoPlexis Corporation 2021 Omnibus Incentive Compensation Plan

Exhibit 10.16 ISOPLEXIS CORPORATION 2021 OMNIBUS INCENTIVE COMPENSATION PLAN SECTION 1. Purpose. The purpose of this 2021 Omnibus Incentive Compensation Plan (the “Plan”) is to enable the Company (as defined below) to grant equity compensation awards and other types of incentive compensation. The Plan is intended to replace the Prior Plan (as defined below), which shall be automatically terminated

Letter Agreement, dated July 22, 2021, by and between IsoPlexis Corporation and Jason Myers

EX-10.13 9 exhibit1013-sx1a1.htm EX-10.13 Exhibit 10.13 IsoPlexis Corporation 35 NE Industrial Road Branford, Connecticut 06405 July 22, 2021 Jason Myers Re: Director Arrangement Dear Jason: I am pleased to confirm our agreement regarding your service to IsoPlexis Corporation, a Delaware corporation, (the “Company”) as a director. We are very pleased to have you on board. This letter sets forth th

Form of Notice of Grant under the IsoPlexis Corporation 2014 Stock Plan

Exhibit 10.15 2014 STOCK PLAN NOTICE OF GRANT Name: [] Address: [ ] [ ] You have been granted an option (the “Option”) to purchase shares of common stock, par value $0.001 per share (the “Common Stock”) of Isoplexis Corporation, a Delaware corporation (the “Company”), subject to the terms and conditions of the Company 2014 Stock Plan and the attached Stock Option Agreement (the “Option Agreement”)

Letter Agreement, dated July 22, 2021, by and between IsoPlexis Corporation and Michael Egholm

EX-10.12 8 exhibit1012s-1a1.htm EX-10.12 Exhibit 10.12 IsoPlexis Corporation 35 NE Industrial Road Branford, Connecticut 06405 July 22, 2021 Michael Egholm Re: Director Arrangement Dear Michael: I am pleased to confirm our agreement regarding your service to IsoPlexis Corporation, a Delaware corporation, (the “Company”) as a director. We are very pleased to have you on board. This letter sets fort

IsoPlexis Corporation 2014 Stock Plan*

Exhibit 10.14 ISOPLEXIS CORPORATION 2014 STOCK PLAN I.GENERAL 1.1.Purpose. The purpose of this equity incentive plan (the ?Plan?) is to secure for IsoPlexis Corporation, a Delaware corporation (the ?Corporation?), and its stockholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or advisors to, the Corporation and any affiliate of the C

As filed with the Securities and Exchange Commission on August 20, 2021.

As filed with the Securities and Exchange Commission on August 20, 2021. Registration No. 333-258046 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organiza

Third Amendment to the License Agreement, executed on July 22, 2021 and effective as of April 10, 2021, by and between IsoPlexis Corporation and Yale University

Exhibit 10.10 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type that the registrant customarily and actually treats as private and confidential. THIRD AMENDMENT TO THE LICENSE AGREEMENT [***] Between IsoPlexis Corporation (?ISOPLEXIS?) and Yale University (?YALE?) PREAMBLE 1) The Parti

FOIA CONFIDENTIAL TREATMENT REQUEST CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THE OMITTED PORTIONS, WHICH HAVE BEEN REPLACED WITH THE F

FOIA CONFIDENTIAL TREATMENT REQUEST CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

Credit Agreement and Guaranty, dated as of December 30, 2020, by and among IsoPlexis Corporation, Perceptive Credit Holdings III, L.P., as administrative agent, and the other parties thereto

EX-10.1 4 exhibit101-sx1.htm EX-10.1 Exhibit 10.1 EXECUTION VERSION CREDIT AGREEMENT AND GUARANTY DATED AS OF DECEMBER 30, 2020 AMONG ISOPLEXIS CORPORATION, AS BORROWER, THE GUARANTORS FROM TIME TO TIME PARTY HERETO, AS GUARANTORS, THE LENDERS FROM TIME TO TIME PARTY HERETO, AS LENDERS, AND PERCEPTIVE CREDIT HOLDINGS III, LP, AS ADMINISTRATIVE AGENT AND AS A LENDER $50,000,000 TABLE OF CONTENTS SE

Second Amendment to the License Agreement, dated as of January 8, 2018, by and between IsoPlexis Corporation and Yale University

EX-10.5 8 exhibit105-sx1.htm EX-10.5 Exhibit 10.5 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type that the registrant customarily and actually treats as private and confidential. SECOND AMENDMENT TO THE LICENSE AGREEMENT [***] Between IsoPlexis Corporation (“ISOPLEXIS”) and Yale Univ

Offer Letter, dated November 18, 2019, by and between IsoPlexis Corporation and John Strahley

Exhibit 10.8 IsoPlexis.com 35 N.E Industrial Rd. Branford, Connecticut. United States 06405 November 18, 2019 John Strahley Dear John, I am very pleased to provide you with a summary of the terms and conditions of your anticipated employment by IsoPlexis Corporation (the ?Company?). The following sets forth the proposed terms and conditions of your offer of employment. We hope that you choose to j

License Agreement, dated as of March 8, 2017, by and between IsoPlexis Corporation and the California Institute of Technology

EX-10.6 9 exhibit106-sx1.htm EX-10.6 Exhibit 10.6 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type that the registrant customarily and actually treats as private and confidential. LICENSE AGREEMENT THIS AGREEMENT is effective as of the 8 day of March, 2017 (the “Effective Date”), betw

Offer Letter, dated May 5, 2020, by and between IsoPlexis Corporation and Peter Siesel

Exhibit 10.9 IsoPlexis.com 35 N.E Industrial Rd. Branford, Connecticut. United States 06405 May 5, 2020 Peter Siesel Dear Peter, I am very pleased to provide you with a summary of the terms and conditions of your anticipated employment by IsoPlexis Corporation (the ?Company?). The following sets forth the proposed terms and conditions of your offer of employment. We hope that you choose to join th

Warrant Certificate, dated as of December 30, 2020, by and between IsoPlexis Corporation and Perceptive Credit Holdings III, LP

EX-4.3 2 exhibit43-sx1.htm EX-4.3 Exhibit 4.3 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWI

First Amendment to Credit Agreement and Guaranty, dated as of May 27, 2021, by and among IsoPlexis Corporation, Perceptive Credit Holdings III, L.P. as administrative agent, and the other parties thereto

Exhibit 10.2 EXECUTION VERSION FIRST AMENDMENT TO CREDIT AGREEMENT AND GUARANTY This First Amendment to Credit Agreement and Guaranty (herein, this “Agreement”) is entered into as of May 27, 2021 (the “First Amendment Effective Date”), by and among IsoPlexis Corporation, a Delaware corporation (the “Borrower”), the Lenders party hereto (each a “Lender” and collectively, the “Lenders”) and Percepti

IsoPlexis Corporation Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted July 2, 2021 CIK No. 0001615055

July 20, 2021 IsoPlexis Corporation Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted July 2, 2021 CIK No. 0001615055 Dear Mmes. Park and Westbrook: IsoPlexis Corporation (the ?Company?) has filed today with the staff (the ?Staff?) of the Securities and Exchange Commission (the ?SEC?), via EDGAR, this letter and the Company?s Registration Statement on Form S-1 (the ?Registratio

Amendment to the License Agreement, dated as of December 19, 2016, by and between IsoPlexis Corporation and Yale University

Exhibit 10.4 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type that the registrant customarily and actually treats as private and confidential. AMENDMENT TO THE LICENSE AGREEMENT [***] Between IsoPlexis Corporation (“ISOPLEXIS”) and Yale University (“YALE”) PREAMBLE 1) The Parties ente

Patent Purchase Agreement, dated as of May 12, 2021, by and among QIAGEN Sciences, LLC, QIAGEN GmbH and IsoPlexis Corporation

Exhibit 10.7 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type that the registrant customarily and actually treats as private and confidential. Patent Purchase Agreement This Patent Purchase Agreement (the “Agreement”) is entered into this 12th day of May 2021 (the "Effective Date") by

Amended and Restated License Agreement, dated as of November 28, 2015, by and between IsoPlexis Corporation and Yale University

Exhibit 10.3 EXECUTION VERSION Yale Confidential [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type that the registrant customarily and actually treats as private and confidential. TABLE OF CONTENTS 1. BACKGROUND 2 2. DEFINITIONS 2 3. LICENSE GRANT AND TERM 7 4. DUE DILIGENCE 8 5. LICEN

Form S-1

As filed with the Securities and Exchange Commission on July 20, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IsoPlexis Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 3826 (Primary Standar

Subsidiaries of IsoPlexis Corporation

Exhibit 21.1 Subsidiaries of IsoPlexis Corporation Entity Name Jurisdiction of Organization IsoPlexis Corporation UK Limited United Kingdom

As confidentially submitted to the Securities and Exchange Commission on July 2, 2021. This Amendment No. 1 to the draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information herein remains

As confidentially submitted to the Securities and Exchange Commission on July 2, 2021.

IsoPlexis Corporation Confidential Submission of Amendment No. 1 to Draft Registration Statement on Form S-1 CIK No. 0001615055

July 2, 2021 IsoPlexis Corporation Confidential Submission of Amendment No. 1 to Draft Registration Statement on Form S-1 CIK No. 0001615055 Dear Mmes. Virginio and Westbrook: IsoPlexis Corporation (the ?Company?) has confidentially submitted today pursuant to Section 6(e) of the Securities Act of 1933, as amended (the ?Securities Act?), via EDGAR, this letter and Amendment No. 1 to the draft Regi

As confidentially submitted to the Securities and Exchange Commission on May 13, 2021. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information herein remains strictly confidential.

As confidentially submitted to the Securities and Exchange Commission on May 13, 2021.

IsoPlexis Corporation Confidential Submission of Draft Registration Statement on Form S-1 CIK No. 0001615055

May 13, 2021 IsoPlexis Corporation Confidential Submission of Draft Registration Statement on Form S-1 CIK No.